Dr. Margaret E. Macy
Claim this profileChildren's Hospital Colorado
Expert in Neuroblastoma
Expert in Tumors
40 reported clinical trials
58 drugs studied
About Margaret E. Macy
Education:
- Obtained MD from the University of Colorado School of Medicine in 2015.
- Completed Pediatrics Residency at Children's Hospital Colorado in 2018.
- Finished Fellowship in Pediatric Hematology/Oncology at Children's Hospital Colorado in 2021.
Experience:
- Currently serves as a Pediatric Hematologist/Oncologist at Children's Hospital Colorado.
- Specializes in pediatric medicine, hematology, and oncology.
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
Stage III
2Tumors
Global LeaderStage IV
NTRK positive
NTRK1 positive
Affiliated Hospitals
Clinical Trials Margaret E. Macy is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Margaret E. Macy
Clinical Trial Related7 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Margaret E. Macy has experience with
- Dinutuximab
- Temozolomide
- Abemaciclib
- Cyclophosphamide
- Irinotecan
- Larotrectinib
Breakdown of trials Margaret E. Macy has run
Neuroblastoma
Tumors
Recurrence
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Margaret E. Macy specialize in?
Margaret E. Macy focuses on Neuroblastoma and Tumors. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Margaret E. Macy currently recruiting for clinical trials?
Yes, Margaret E. Macy is currently recruiting for 12 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Margaret E. Macy has studied deeply?
Yes, Margaret E. Macy has studied treatments such as Dinutuximab, Temozolomide, Abemaciclib.
What is the best way to schedule an appointment with Margaret E. Macy?
Apply for one of the trials that Margaret E. Macy is conducting.
What is the office address of Margaret E. Macy?
The office of Margaret E. Macy is located at: Children's Hospital Colorado, Aurora, Colorado 80045 United States. This is the address for their practice at the Children's Hospital Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.